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Identification of genetic 
susceptibility loci for intestinal 
Behçet’s disease
Seung Won Kim1,2,3,*, Yoon Suk Jung4,*, Jae Bum Ahn5, Eun-Soon Shin6, Hui Won Jang1, 
Hyun Jung Lee1, Tae Il Kim1, Do Young Kim7, Dongsik Bang8, Won Ho Kim1 & 
Jae Hee Cheon1,2,3
Several recent genome-wide association studies (GWAS) identified susceptibility loci/genes for 
Behçet’s disease (BD). However, no study has specifically investigated the genetic susceptibility loci 
associated with intestinal involvement in BD. We aimed to identify distinctive genetic susceptibility 
loci/genes associated with intestinal involvement in BD and determine their roles in intestinal 
inflammation as well as their interactions with genes involved in inflammatory bowel disease (IBD). 
GWAS and validation studies showed intestinal BD-specific associations with an NAALADL2 gene locus 
(rs3914501, P = 3.8 × 10−4) and a YIPF7 gene locus (rs6838327, P = 3.5 × 10−4). Validation, haplotype, 
and pathway analyses showed distinct genetic architectures between intestinal BD and BD without 
intestinal involvement. Furthermore, network analysis revealed shared pathogenic pathways between 
intestinal BD and IBD. Gene functional analyses indicated that down-regulation of NAALADL2 and 
YIPF7 expression was associated with exacerbating intestinal inflammatory responses both in vitro and 
in vivo. Our results provide new insights into intestinal BD-specific genetic variations, which represents 
a distinct pathway from BD without intestinal involvement. Functional consequences of the intestinal 
BD-specific NAALADL2 and YIPF7 expression patterns proved a suggestive association with intestinal 
inflammation risk, which warrants further validation.
Behçet’s disease (BD) is a rare, chronic, inflammatory, multi-systemic disorder characterized by recurrent oral 
and genital ulcers, ocular lesions, skin manifestations, and arthritis, as well as vascular, neurological, and intesti-
nal involvement1,2. Multiple factors, including undefined environmental components and host genetic changes, 
cooperatively interact and participate in the development of the disease1–3. Although the nature of these genetic 
variants remains unknown for the most part, various genetic risk factors are considered to contribute to the 
disease susceptibility2–5. In addition to human leukocyte antigen gene encoding B*51 (HLA-B*51) and regions 
encompassing major histocompatibility complex (MHC) class I, genome-wide association studies (GWAS) have 
identified several other BD susceptibility genes, including interleukin (IL)10, IL23 receptor (IL23R), IL12 recep-
tor beta 2 (IL12RB2), C-C chemokine receptor 1 gene (CCR1), signal transducer and activator of transcription 
(STAT4), genes encoding killer cell lectin-like receptor family members (KLRC4-KLRK1), and endoplasmic retic-
ulum aminopeptidase (ERAP1)2–6.
Intestinal BD (BD with intestinal involvement) is diagnosed when there is a typically shaped ulcer in the 
gastrointestinal tract, and clinical findings meet the diagnostic criteria for BD7. Intestinal BD can result in severe 
complications, including bowel perforation and extensive hemorrhage, and is therefore one of the major causes 
of morbidity and mortality in patients with BD8. Intestinal involvement is rare in Mediterranean BD patients 
(0 to 3%)9, whereas it is relatively more prevalent in East Asia, including Korea and Japan (5–25%)10. Given these 
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geographic and racial differences in the incidence of BD with or without intestinal involvement, intestinal BD is 
likely to be associated with pathogenic pathways that are distinct from those contributed to BD without intestinal 
involvement. Some phenotypic overlaps (inflammation in the eyes, skin, and intestine); shared genetic associa-
tions in the MHC class I region, IL10, and IL23R; and the effectiveness of tumor necrosis factor (TNF)-α blockade 
also imply common pathogenic pathways between BD and inflammatory bowel disease (IBD)11,12. Given that 
IBD and intestinal BD share a number of clinical phenotypes in terms of intestinal manifestations, therapeutic 
applications, and clinical courses12, they may show a shared inherited susceptibility mechanism. However, intes-
tinal BD and IBD have also been considered as two distinct diseases by some authors. Thus, there may be specific 
genetic markers for intestinal BD that are different from those for IBD. Although GWAS have revealed several 
genetic susceptibility loci associated with BD development2–6, all of these studies focused on BD itself. The specific 
genetic factors associated with intestinal BD have not yet been examined, which is mainly owing to the rarity of 
the disease.
In this study, we sought to discover specific genetic susceptibility loci associated with intestinal BD, through 
GWAS and replication studies in the Korean population. This study was performed with the intention of defining 
specific genetic markers for intestinal BD. We also investigated the functional consequences of genetic factors that 
influence both disease susceptibility and BD phenotypes with intestinal involvement, as well as shared pathogenic 
pathways related to IBD.
Results
GWAS of intestinal BD and single nucleotide polymorphism (SNP) selection. A GWAS was per-
formed including 100 BD patients without intestinal involvement, 99 patients with intestinal BD, and 597 con-
trols. The results of principal components analysis (PCA) showed no stratification resulting from the population 
admixture, similar to the previous Korean IBD GWAS data13,14 (Fig. S1). An overview of the clinical characteris-
tics of the study samples is provided in Table 1. We focused on independent polygenic factors specifically related 
to intestinal BD, because we hypothesized that intestinal BD originates from additional polygenic factors that 
might be different from those related to BD without intestinal involvement. The detailed workflow of our associ-
ation studies is depicted in Fig. S2.
First, intestinal BD and BD without intestinal involvement were directly compared, but none of the SNPs was 
significant after conservative Bonferroni correction, owing to the small sample size. Therefore, the SNPs showing 
the lowest P values in our GWAS were subjected to a validation test, including rs6838327 in YIPF7 in a clustered 
genomic locus on chromosome 4, rs7941240 on chromosome 11 in the intergenic region, and rs2655653 on chro-
mosome 6 in the intergenic region (Fig. S2a). Next, to exclude any genetic factors related to BD without intestinal 
BD without intestinal 
involvement (n = 238)
Intestinal BD 
(n = 295)
Sex, male (%) 62 (26.1) 135 (45.8)
Mean age (years) 41.8 ± 11.8 44.3 ± 12.3
Mean age at diagnosis (years) 35.5 ± 10.8 40.1 ± 11.8
Mean disease duration (years) 5.9 ± 6.9 7.5 ± 5.7
HLA-B51 positivity (%)A 83/226 (36.7) 23/102 (22.5)*
Clinical manifestations (%)
 Oral ulcers 238 (100) 273 (92.5)
 Genital ulcers 212 (89.1) 154 (52.2)
 Eye lesions 76 (31.9) 52 (17.6)
 Skin lesions 219 (92.0) 192 (65.1)
 Arthritis/arthralgia 134 (56.3) 158 (53.6)
 Vascular lesions 10 (4.2) 11 (3.7)
 Central nervous system lesions 5 (2.1) 5 (1.7)
 Epididymitis 3 (1.3) 0
Intestinal complications (%)
 Perforation 0 (0.0) 28 (9.5)
 Fistula 0 (0.0) 26 (8.8)
 Stricture 0 (0.0) 25 (8.5)
 Abscess 0 (0.0) 13 (4.4)
Medication use (%)
 5-aminosalicylic acid/ sulfasalazine 0 (0.0) 288 (97.6)
Corticosteroids 124 (52.1) 136 (46.1)
Azathiopurine/6-mercaptopurine 24 (10.1) 107 (36.3)
Anti-TNF agent 0 (0.0) 8 (2.7)
Table 1.  Clinical and demographic characteristics of Behçet’s disease without and with intestinal 
involvement. BD, Behcet’s disease; HLA, human leukocyte antigen; TNF, tumor necrosis factor; NA, not 
applicable. *P < 0.05 vs. BD without intestinal involvement. AData are available for 226 BD patients without 
intestinal involvement and 102 intestinal BD patients.
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involvement, only the loci that were significant in intestinal BD and were not significant in the comparison of BD 
without intestinal involvement to healthy controls were reanalyzed. As a result, only two SNPs in non-clustered 
regions met the genome-wide significance threshold, of which only one SNP with the lowest P value (rs4500591; 
near MIR548F5 and NBEA; P = 8.8 × 10−16) was selected for the next step. Furthermore, 12 additional signif-
icant SNPs from four clustered genomic loci (DCAF12, PLCB1, ELMO1, and NAALADL2) were included for 
validation, even though the significance level did not reach the Bonferroni correction threshold (Fig. S2b and 
Supporting information 2). BD patients without intestinal involvement were also compared to the healthy con-
trol group. Among 342 significant SNPs, there were 6 clustered SNPs, including 2 genomic loci (LOC284395, 
CD300LB), that met the Bonferroni threshold. Among these, we selected one SNP in LOC284395, presenting the 
lowest P value (rs7245731, P = 1.9 × 10−9; Fig. S2c). The SNP in CD300LB (rs61730133) was identified as a sus-
ceptibility locus for BD without intestinal involvement. This SNP was also detected in the imputation analysis as 
an intestinal BD-specific gene (Fig. S2d and Supporting information 2). Finally, we compared the 32 BD-specific 
SNPs with significant P values between the intestinal BD and BD without intestinal involvement comparison, and 
selected one SNP (rs32019, CD180; Fig. S2e) for further analysis. Manhattan and regional association plots in the 
discovery group were constructed to provide a detailed overview of the disease-associated regions, as shown in 
Figs S3 and S4. Overall, 19 SNPs from our GWAS were chosen to be validated.
The combinations of multiple variants with small effects helps to explain the overall susceptibility to a multi-
factorial disease15. Therefore, a haplotype analysis was conducted with additional proxy SNPs to better evaluate 
the genetic associations at the haplotype level. As a result, 12 additional SNPs were selected for the validation 
study. Finally, 13 previously reported potential candidate SNPs were validated after literature review. Collectively, 
44 selected SNPs were used in a replication study, including 196 independent patients with intestinal BD, 138 
BD patients without intestinal involvement, and 391 healthy controls, to validate the GWAS screening results 
(Supporting information 3).
Validation study results. A comparison of SNPs between intestinal BD and BD without intestinal involve-
ment showed an intestinal BD-specific association of the YIPF7 gene locus (rs6838327, odds ratio [OR] = 1.567, 
combined P = 3.5 × 10−4, Table 2) after Bonferroni correction (P < 0.05/44 SNPs). In addition, the NAALADL2 
locus on chromosome 3 (rs3914501) showed a significant association with the development of intestinal BD 
(OR = 1.914, P = 3.8 × 10−4, Table 3) in the combined analysis and modest evidence of an association in the 
replication analysis (P = 1.6 × 10−2). Notably, among the genetic loci implicated in previous GWAS2–6,16, 
IL10 and ERAP1 also showed modest associations with intestinal BD (rs1518111, combined P = 7.6 × 10−3, 
Table 3; rs2927615, combined P = 1.6 × 10−2), and HLA-B (near PSORS1C1) was significantly associated with 
BD without intestinal involvement compared to healthy controls (rs4959053, combined P = 6.6 × 10−5, P rep-
lication = 4.6 × 10−3; rs12525170, combined P = 1.3 × 10−5, P replication = 1.1 × 10−5, Table 4). However, 
CCR1-CCR3, IL23R-IL12RB2, HLA-F-AS1–HLA-A, STAT4, and KLRC4-KLRK1 did not show significant 
SNP MA Locus Nearby genes†
GWAS Replicated Combined
P Model
aP value 
Model
MAF: BD 
without 
intestinal 
involvement
MAF: 
Intestinal 
BD
aP value 
Model OR (95% CI)
MAF: BD 
without 
intestinal 
involvement
MAF: 
Intestinal 
BD
rs284148 T Chr.1:92277843 TGFBR3
6.4 × 10−4
Recessive
6.0 × 10−1
Recessive 0.417 0.420
1.7 × 10−2
Dominant
0.638
(0.442–0.921) 0.446 0.381
rs16848171 C Chr. 3:175181067 NAALADL2
4.9 × 10−3
Recessive
5.4 × 10−2
Recessive 0.195 0.227
7.4 × 10−3
Recessive
3.208
(1.367–7.529) 0.217 0.248
rs6838327 A Chr. 4:44626846 YIPF7
6.2 × 10−6
Allelic
4.8 × 10−1
Allelic 0.456 0.482
3.5 × 10−4
Allelic
1.567
(1.225–2.005) 0.408 0.519
rs2927615* A Chr. 5:96198202 ERAP1-ERAP2 —
5.9 × 10−2
Allelic 0.010 0.033
2.0 × 10−2
Allelic
2.744
(1.172–6.427) 0.016 0.041
rs12525170 A Chr. 6:31099761 HLA-B —
1.5 × 10−1
Dominant 0.195 0.161
6.0 × 10−3
Dominant
0.595
(0.410–0.862) 0.212 0.151
rs4959053* A Chr. 6:31099577 HLA-B
8.2 × 10−3
Allelic
3.0 × 10−1
Allelic 0.185 0.156
1.8 × 10−2
Allelic
0.619
(0.425–0.9) 0.204 0.148
rs7245731 A Chr. 19:29975118 LOC284395
9.2 × 10−2
Recessive
2.6 × 10−1
Recessive 0.109 0.125
4.2 × 10−2
Recessive
0.113
(0.014–0.925) 0.139 0.127
rs6086653 G Chr.20:8838343 PLCB1
7.8 × 10−2
Recessive
4.7 × 10−2
Recessive 0.734 0.668
1.7 × 10−2
Recessive
0.467
(0.250–0.874) 0.729 0.707
Table 2.  Association results of comparison between patients with intestinal Behçet’s disease and patients 
with Behçet’s disease without intestinal involvement. The combined analysis were performed 238 BD cases 
without intestinal involvement including 100 samples used in GWAS and 295 intestinal BD samples including 
99 samples used in GWAS. Bonferroni-corrected significance level is calculated as 0.05/44 tests (bold). SNP, 
single nucleotide polymorphism; Chr., chromosome; MA, minor allele; GWAS, genome-wide association 
study; OR, odds ratio; 95% CI, 95% confidence interval; MAF, minor allele frequency. aP value: P value from 
logistic regression analysis adjusted for sex and age. *Discovered loci described previously in BD GWAS. Allele 
frequencies are presented for the discovery sample. †Nearby genes are defined as the closest genes to the SNP 
within signal boundary or the closest genes within a 200-kb window.
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associations with any BD subtypes in our study, which might be due to the limited sample size or differences in 
ethnic background effects on disease development. Our validation stage had sufficient power (≥ 0.8) to detect an 
OR of 2.5 for the YIPF7 SNP with a minor allele frequency (MAF) of 0.43, and an OR of 2.2 for the HLA-B SNP 
with an MAF of 0.13 (Table S1). Data for all of the replicated SNPs are summarized in Supporting information 3.
Haplotype analysis. We performed a haplotype analysis to further elucidate the genetic factors involved in 
intestinal BD pathogenesis. In the haplotype analysis (Table S2), DCAF12 (C-A, P = 2.4 × 10−3), IL10 (G-C-C, 
P = 7.3 × 10−3), PLCB1 (C-C-T-T-G, P = 1.5 × 10−2), SCHIP1 (G-C, P = 3.2 × 10−3), and TGFBR3 (C-C-G, 
P = 2.2 × 10−2) showed associations with intestinal BD development. These results indicate that these genes 
are potential causal variants that contribute to intestinal BD development. In contrast, HLA-B showed associ-
ations with BD without intestinal involvement (G-A-A, P = 2.4 × 10−5). The associations of NAALADL2 (C-G, 
P = 1.2 × 10−2) and loci near HLA-B (G-A-A, P = 9.7 × 10−3) were significant in the comparison between intes-
tinal BD and BD without intestinal involvement. These different genetic risks reflect the specificity of biological 
genetic markers for intestinal involvement.
SNP MA Locus Nearby genes†
GWAS Replicated Combined
P Model aP value Model
MAF: 
Intestinal 
BD aP value Model OR (95% CI)
MAF: 
Intestinal 
BD
MAF: 
Healthy 
control
rs1554286* G Chr. 1:206944233 IL10
7.6 × 10−1
Codominant
4.0 × 10−3
Codominant 0.237
7.6 × 10−3
Codominant
0.717
(0.562–0.915) 0.252 0.318
rs1800871* C Chr. 1:206946634 IL10 —
5.8 × 10−3
Codominant 0.232
9.1 × 10−3
Codominant
0.722
(0.564–0.922) 0.245 0.309
rs1518111* C Chr. 1:206944645 IL10 —
5.4 × 10−3
Allelic 0.234
7.6 × 10−3
Allelic
0.717
(0.562–0.916) 0.247 0.313
rs7556581 A Chr. 1:116386105 NHLH2
7.1 × 10−5
Recessive
3.7 × 10−1
Recessive 0.379
1.1 × 10−2
Recessive
1.731
(1.131–2.649) 0.402 0.350
rs284148 T Chr.1:92277843 TGFBR3
8.8 × 10−5
Dominant
3.5 × 10−1
Dominant 0.420
1.2 × 10−2
Dominant
0.667
(0.486–0.916) 0.381 0.425
rs16830589 C Chr.3:159365432 SCHIP1
2.5 × 10−5
Dominant
2.0 × 10−1
Dominant 0.204
4.7 × 10−3
Dominant
1.579
(1.15–2.167) 0.231 0.182
rs16830581 G Chr.3:159362915 SCHIP1
1.5 × 10−5
Dominant
3.4 × 10−1
Dominant 0.194
7.6 × 10−3
Dominant
1.544
(1.122–2.126) 0.225 0.178
rs3914501 G Chr. 3:174564668 NAALADL2
5.7 × 10−5
Recessive
1.6 × 10−2
Recessive 0.505
3.8 × 10−4
Recessive
1.914
(1.338–2.738) 0.537 0.459
rs16848171 C Chr. 3:174564668 NAALADL2
4.0 × 10−5
Recessive
9.3 × 10−2
Recessive 0.227
7.0 × 10−3
Recessive
2.462
(1.279–4.739) 0.248 0.219
rs6838327 A Chr. 4:44626846 YIPF7
4.6 × 10−3
Recessive
1.2 × 10−1
Recessive 0.482
6.4 × 10−3
Recessive
1.654
(1.152–2.376) 0.519 0.468
rs32019 C Chr. 5:66702373 CD180 —
4.4 × 10−2
Codominant 0.551
4.0 × 10−3
Codominant
1.265
(1.023–1.563) 0.548 0.487
rs10259514 G Chr. 7:36829705 ELMO1
4.3 × 10−5
Allelic
1.4 × 10−1
Allelic 0.277
4.8 × 10−3
Allelic
0.706
(0.554–0.899) 0.249 0.320
rs10441723 C Chr. 9:34082144 DCAF12
4.2 × 10−5
Codominant
3.5 × 10−1
Codominant 0.295
9.5 × 10−3
Codominant
0.725
(0.568–0.924) 0.256 0.321
rs10758242 A Chr. 9:34146776 DCAF12
2.6 × 10−5
Allelic
2.1 × 10−1
Allelic 0.283
2.8 × 10−3
Allelic
0.689
(0.54–0.88) 0.245 0.320
rs12624809 C Chr.20:8822431 PLCB1
8.5 × 10−6
Dominant
6.5 × 10−1
Dominant 0.653
3.0 × 10−2
Dominant
1.403
(1.034–1.905) 0.696 0.671
rs6086632 C Chr.20:8822931 PLCB1
7.8 × 10−6
Dominant
7.9 × 10−1
Dominant 0.649
3.7 × 10−2
Dominant
1.385
(1.019–1.880) 0.694 0.671
rs6086633 T Chr.20:8823064 PLCB1
6.8 × 10−6
Dominant
7.4 × 10−1
Dominant 0.652
3.7 × 10−2
Dominant
1.383
(1.019–1.876) 0.695 0.671
rs6039302 T Chr.20:8831137 PLCB1
1.1 × 10−5
Dominant
7.1 × 10−1
Dominant 0658
3.3 × 10−2
Dominant
1.397
(1.028–1.898) 0.701 0.675
rs6086653 G Chr.20:8838343 PLCB1
3.5 × 10−5
Dominant
6.2 × 10−1
Dominant 0.668
4.3 × 10−2
Dominant
1.371
(1.010–1.862) 0.707 0.688
Table 3.  Association results of comparison between healthy controls and patients with intestinal Behçet’s 
disease. The combined analysis were performed 391 healthy controls and 295 intestinal BD samples including 
99 samples used in GWAS. Bonferroni-corrected significance level is calculated as 0.05/44 tests (bold). SNP, 
single nucleotide polymorphism; Chr., chromosome; MA, minor allele; GWAS, genome-wide association 
study; OR, odds ratio; 95% CI, 95% confidence interval; MAF, minor allele frequency. aP value: P value from 
logistic regression analysis adjusted for sex and age. *Discovered loci described previously. Allele frequencies 
are presented for the discovery sample. †Nearby genes are defined as the closest genes to the SNP within signal 
boundary or the closest genes within a 200-kb window.
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Clinical outcomes according to genotype. We assessed whether the investigated SNPs could influence 
clinical manifestations and prognosis, including intestinal complications and the cumulative probabilities of sur-
gery, hospitalization, corticosteroid use, and immunosuppressant use, in patients with intestinal BD. The risk 
allele of rs3914501 in NAALADL2 was associated with a higher cumulative probability of surgery (Fig. 1a). In 
addition, rs3914501 and rs16848171 risk alleles showed modest associations with a higher cumulative proba-
bility of hospitalization and corticosteroid use, respectively (Fig. S5), suggesting their association with a poorer 
prognosis. DCAF12 (rs10758242) and TGFBR3 (rs284148) showed modest associations with intestinal fistula 
development and intestinal stricture, respectively (Table S3). HLA-B genotype showed a strong association with 
HLA-B*51 positivity in both intestinal BD patients (OR: 26.07, Table S3) and BD patients without intestinal 
involvement (OR: 56.53, Table S4). HLA-B genotype also showed a strong association with central nervous system 
lesions (OR: 23.23, Table S4) in BD patients without intestinal involvement.
Pathway analysis. Functionally related genes collectively contribute to disease susceptibility, including loci 
that do not reach the genome-wide significance threshold individually17. Ingenuity Pathway Analysis (IPA) based 
on published data was used to identify the potential biological pathways of the genes responsible for disease sus-
ceptibility for the validated SNPs (P < 0.05). Overlap between significant regions was examined according to the 
published GWAS results (GWAS catalog: Supporting information 6). Notably, the pathway analyses showed that 
intestinal BD genes (13 genes) comprise a single functional network, including 8 focus molecules that overlapped 
with eight networks (IL10, NFκ B, ERAP1, FOS, UBC, UBC, APP, UBC) for the genes identified in the IBD GWAS 
(Fig. 1b). These results indicate that the phenotype of intestinal BD shares some common pathogenic risk factors 
with IBD (Fig. S6a). Intestinal BD-related genes have only one network (ERAP1, IL10) with 14 genes derived 
from the previous BD GWAS catalog, which may also indirectly connect the intestinal BD pathway to the IBD 
networks (IL23R, IL12, Figs 1c and S6c). NAALADL2 was included in the pathway analysis with the IBD genes, 
but YIPF7 was not included because the exact function of this protein remains unknown. The functional net-
work showed potential functions in common for PI3K signaling in B lymphocytes (PLCB1, CD180) and CXCR4 
(PLCB1, ELMO1) signaling with two focus molecules (CD180, ELMO1) related to five genes for BD without 
intestinal involvement (Fig. S6b). This indicates that some intestinal BD genes contribute to BD phenotypes 
through interactions with genes for BD without intestinal involvement.
Gene functional analysis of NAALADL2 and YIPF7. Next, we validated these associations using 
experimental functional studies to complement our genetic study results. Immunohistochemical analyses for 
NAALADL2 and YIPF7 were performed using inflamed colon tissues obtained from patients with intestinal BD 
or IBD and normal colon tissues obtained from patients with colorectal cancer after intestinal surgery. The pro-
tein expression levels of NAALADL2 and YIPF7 were significantly decreased in the tissues of patients with IBD 
and intestinal BD compared to those in control tissues. The difference was more dramatic in patients with risk 
alleles than in those without risk alleles (Fig. 2a,b).
Concordantly, the mRNA levels of NAALADL2 and YIPF7 in the inflamed colon tissues of mice were lower 
than control mice, respectively (Fig. 2c). In addition, the colon tissues of patients with intestinal BD showed 
increased IL17 mRNA expression levels, along with decreased IL10 mRNA expression levels (Fig. 2d). Previous 
studies indicate that perturbed homeostasis between commensal bacteria and mucosal immunity serves as a crit-
ical determinant in the development of gut inflammation in IBD for a genetically susceptible individual18,19. In 
SNP MA Locus
Nearby 
genes†
GWAS Replicated Combined
P Model aP value Model
MAF: BD 
without intestinal 
involvement a P value Model OR (95% CI)
MAF: BD 
without intestinal 
involvement
MAF: 
Healthy 
Control
rs6838327 A Chr. 4:44626846 YIPF7
4.4 × 10−4
Dominant
3.6 × 10−1
Dominant 0.415
3.1 × 10−2
Dominant
0.630
(0.442–0.897) 0.456 0.468
rs32019 C Chr. 5:66702373 CD180
4.0 × 10−1
Recessive
1.2 × 10−2
Recessive 0.474
4.0 × 10−2
Recessive
0.658
(0.442–0.98) 0.461 0.487
rs4959053* A Chr. 6:31099577 HLA-B
2.2 × 10−5
Allelic
4.6 × 10−3
Allelic 0.207
6.6 × 10−5
Allelic
1.892
(1.383–2.589) 0.185 0.119
rs12525170* A Chr. 6:31099761
HLA-B,
PSORS1C1 —
1.1 × 10−5
Dominant 0.213
1.3 × 10−5
Dominant
2.210
(1.546–3.157) 0.195 0.119
rs10259514 G Chr. 7:36829705 ELMO1
1.9 × 10−2
Codominant
1.7 × 10−2
Codominant 0.257
1.7 × 10−2
Codominant
0.724
(0.556–0.944) 0.245 0.320
Table 4.  Association results of comparison between healthy controls and patients with Behçet’s disease 
without intestinal involvement. The combined analysis was performed on 391 healthy controls and 238 
BD cases without intestinal involvement, including 100 samples used in GWAS. SNP, single nucleotide 
polymorphism; Chr., chromosome; MA, minor allele; GWAS, genome-wide association study; OR, odds 
ratio; 95% CI, 95% confidence interval; MAF, minor allele frequency. aP value: P value from logistic regression 
analysis adjusted for sex and age. *Discovered loci described previously. Allele frequencies are presented for 
the discovery sample. †Nearby genes are defined as the closest genes to the SNP within signal boundary or the 
closest genes within a 200-kb window. Bonferroni-corrected significance level is calculated as 0.05/44 tests 
(bold).
www.nature.com/scientificreports/
6Scientific RepoRts | 7:39850 | DOI: 10.1038/srep39850
addition, aberrant Toll-like receptor (TLR) modulation, such as TLR4, by lipopolysaccharide (LPS), an important 
stimulator of cytokines such as TNF-α , may contribute to the development of IBD20. Thus, additional functional 
studies were conducted in intestinal epithelial cells using LPS stimulation. LPS reduced NAALADL2 and YIPF7 
protein and mRNA levels in HT-29 cells (Fig. 3a,b). Furthermore, knockdown of NAALADL2 and YIPF7 by short 
interfering RNAs (siRNAs) resulted in higher TNF mRNA levels than controls (Figs 3c,d and S7).
Discussion
Variations of clinical phenotypes in patients with BD are well known, but the underlying contribution of genetic 
variations to these phenotypes has not yet been explored. Here lies the novel contribution of our GWAS. We 
identified intestinal BD-specific associations of loci near NAALADL2 and YIPF7. An SNP in NAALADL2 
(rs62285902) was also previously identified as a candidate gene in the Crohn’s disease genome-wide imputation 
analysis of the Japanese population21. In addition, the NAALADL2-associated rs3914501 risk allele was reported 
to be linked to the development of Kawasaki disease and Cornelia de Lange syndrome, a rare developmental 
malformation syndrome22. Since Kawasaki disease affects blood vessels and BD is also a form of vasculitis, the 
fact that NAALADL2 showed a novel association with intestinal BD in both our replication and subsequent hap-
lotype analyses is intriguing. Moreover, the NAALADL2-associated rs3914501 risk allele was associated with 
poor prognosis of intestinal BD. Dysfunction of YIP1 family members may deregulate intestinal homeostasis, 
leading to a pathogenic state23. Mice with null mutated Yipf6 were extremely sensitive to dextran sodium sulfate 
(DSS)-induced colitis. Consistently, we newly identified more frequent variations of YIPF7, another YIP1 family 
member, in patients with intestinal BD than in those without intestinal BD.
Figure 1. Clinical outcomes according to NAALADL2 genotype and pathway analysis. (a) Cumulative 
probabilities of surgery according to NAALADL2 genotype in patients with intestinal Behçet’s disease (BD). 
The prognosis of intestinal BD was analyzed using the Kaplan–Meier method with differences determined by 
the log-rank test. Blue lines show risk alleles. (b,c) Network Diagrams of BD susceptibility genes. (b) Networks 
of overlap between intestinal BD (purple) and inflammatory bowel disease (IBD, blue). Blue lines show the 
connection of intestinal BD pathways with those of IBD. (c) Networks of overlap between intestinal BD (purple) 
and BD without intestinal involvement (red). Pink lines show the connection of BD pathways with those of IBD.
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Although IHC and mRNA results cannot explain the causal relationships between the candidate genes and 
disease, they do support the hypothesis of an association between genetic variation and alteration of gene expres-
sion, which can be indirectly be represented by altered IHC and mRNA expression levels of NAALADL2 and 
YIPF7. Supporting these results, SNPs in NAALADL2 and YIPF7 presented transcriptional regulatory activities to 
directly influence their expression (Supporting information 4, RegulomeDB and Haploreg). Moreover, we showed 
that the expression levels of two genes were reduced by LPS, which consequently upregulated TNF-α expression. 
We think that these two genes are the mediators of LPS signaling, and the downregulation of the expression of 
these two genes from genetic variations due to mRNA or protein instability might upregulate TNF-α expression 
and aggravate colitis. Perturbed homeostasis between commensal bacteria and mucosal immunity serves as a 
critical determinant in the development of gut inflammation in inflammatory bowel disease (IBD) for genetically 
susceptible individuals18. Aberrant modulation of TLRs (e.g., TLR4) by LPS, an important stimulator of cytokines 
such as TNF-α , may contribute to the development of IBD20. We used LPS as a microbial triggering factor of 
intestinal bacteria for the initiation of homeostasis disruption. TNF-α is a key cytokine in the pathogenesis of IBD 
and BD, and its blockade is now commonly used as a standard therapy for IBD and BD clinical practice. In fact, 
both genes showed higher expression in crypts than in the lamina propria (data not shown), suggesting that the 
genes function in epithelial cells rather than in immune cells and may affect TNF-α expression. Thus, we suggest 
that TNF-α expression will affect the downstream signaling of immune cells. Furthermore, since an expression 
Figure 2. Gene expression analyses in the colons of patients with Behçet’s disease and inflammatory 
bowel disease and the inflamed colons of mice. (a,b) Immunohistochemistry of NAALADL2 (a) and YIPF7 
(b). Right panels show expression scores according to diseases and SNP genotypes (NAALADL2, rs3914501; 
YIPF7: rs6838327). Pink and blue show NAALADL2 and the nucleus, respectively. The genotype is indicated 
in parentheses. (c,d) mRNA levels in inflamed colon tissues. (c) Transcript levels of NAALADL2 from 
control, TNBS-, and DSS-treated mouse colon tissues. Data represent mean ± SEM. (d) Transcript levels of 
IL17 and IL10 in colon tissues from control and intestinal BD patients (controls, n = 7; intestinal BD, n = 8). 
mRNA levels were quantified by qRT-PCR. *P < 0.05 vs. CTL, **P < 0.005 vs. CTL or Sham. Data represent 
mean ± SD. BD, intestinal Behçet’s diseases; CTL, control; IBD, inflammatory bowel disease; TNBS, 2,4 
6-trinitrobenzenesulfonic acid; DSS, dextran sulfate sodium.
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quantitative loci (eQTL) analysis provided suggestive evidence that rs3914501 in NAALADL2 and rs6838327 in 
YIPF7 upregulate the expression of IL13, IL22, and IL12RB2 in lymphoid cells (Fig. S9 and Supporting informa-
tion 4, eQTL), we thought that its effects on IL22 would also be feasible in epithelial cells. Consistently, our data 
showed increased IL17 mRNA expression levels in the colon tissues of intestinal BD patients along with decreased 
IL10 mRNA expression levels, which was well correlated with the decreased protein levels of NAALADL2 and 
YIPF7 in inflamed cells or tissues, including colonic enterocytes from patients with intestinal BD and IBD, the 
inflamed mouse colon, and LPS-treated HT-29 cells. Taken together, our results suggest that SNPs of NAALADL2 
and YIPF7 are candidates as causal variants of intestinal BD development.
Notably, GWAS cannot provide supporting evidence based on more complex patterns of associations with 
other polymorphisms in the same gene24. In addition, other unknown variants in regions showing high linkage 
disequilibrium of the investigated loci may alter protein expression, translation, or degradation25,26. Hence, we 
performed haplotype and pathway analyses to further elucidate the genetic factors involved in intestinal BD 
pathogenesis. In particular, pathways consisting of combinations of multiple variants with small effects could 
explain the overall susceptibility to multifactorial diseases that cause the same disease phenotype in complex 
diseases15. It has been reported that HLA-B*51, the genetic risk factor most strongly associated with BD in several 
populations2,4,27, is associated with a moderately higher prevalence of genital ulcers, ocular manifestations, and 
skin manifestations, although it showed a decreased prevalence of gastrointestinal involvement in BD28 and no 
relationship with IBD29. Similarly, our results showed that the rate of HLA-B51 positivity was significantly higher 
in BD patients without intestinal involvement than that in intestinal BD patients (36.7% vs. 22.5%, P = 0.011, 
Table 1) in concordance with the genetic results (Table 2). In addition, HLA-B genotype showed a stronger cor-
relation with HLA-B*51 positivity in BD patients without intestinal involvement (OR: 56.53, Table S4) than in 
intestinal BD (OR: 26.07, Table S3). Based on our results and a previous meta-analysis28, genotyping of this allele 
seems to be less associated with intestinal BD and more strongly associated with BD patients without intestinal 
involvement.
The IL10 knockout model is one of the best knockout animal models of IBD30. IL10 protects against colonic 
inflammation31,32. Concordantly, IL10 was found to be more responsible for intestinal BD than for BD without 
intestinal involvement in our genetic association study, including the haplotype analyses. Moreover, the pathway 
analysis revealed connection networks between the intestinal BD and IBD pathways through IL10, and the gene 
expression analysis showed that the IL10 expression level was reduced in the inflamed BD colon. In this context, 
there is strong evidence supporting a potential regulatory function of SNPs in IL10 by affecting the CREB bind-
ing protein (Supporting information 4, RegulomeDB). These results support that IL10 is an example of a shared 
genetic pathogenesis factor between IBD and intestinal BD33,34. The risk alleles in IL10 and HLA-B up-regulate 
the expression of pro-inflammatory cytokines (Fig. S9 and Supporting information 4), suggesting that many risk 
Figure 3. Functional analyses of NAALADL2 and YIPF7 in human intestinal epithelial cells.  
(a) Immunofluorescent staining for NAALADL2 and YIPF7 in HT-29 cells after 1 μ g/mL lipopolysaccharide 
(LPS) treatment for 24 h. Orange, NAALADL2; red, YIPF7; blue, DAPI. (b–d) mRNA quantification. 
mRNA levels of NAALADL2 and YIPF7 in HT-29 cells after LPS treatment for 4 h (b) and after short 
interfering RNA (siRNA) treatment for 24 h (c). (d) TNFA mRNA levels in gene-knockdown cells 
(siNAALADL2 and siYIPF7, respectively). Data represent mean ± SEM (n = 3). mRNA levels were 
quantified by qRT-PCR.
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variants have multiple regulatory and functional features at their loci and interact with each other. Collectively, 
our findings strongly suggest both differences and similarities between the pathways of BD with and without 
intestinal involvement and those of IBD, suggesting overlapping yet distinct genetic architectures for these two 
diseases.
Haplotype analysis suggested phospholipase C beta 1 (PLCB1), transforming growth factor, beta receptor 3 
(TGFBR3), DDB1 and CUL4 associated factor 12 (DCAF12), and schwannomin interacting protein 1 (SCHIP1) as 
potential causal variants of intestinal BD, although they failed to reach significance in the Bonferroni test in a rep-
lication study (Supplementary information 4). PLCB1 is the major nuclear PLC-β isozyme, and its expression was 
reported to be increased in the proliferating crypt compartments of the mouse intestine35. Interactions between 
gut microbiota and intestinal epithelial cells trigger increased DUOX enzymatic activity via PLC-β -dependent 
production of inositol-1,4,5-trisphosphate36. Regulatory and eQTL SNPs of TGFBR3 (rs1805110 and rs17882828, 
respectively) were identified in this study (Supporting information 4). Although other groups have reported BD 
polymorphisms37,38, TGFBR3 is also known to function in the development of colon diseases such as cancer39,40. 
DCAF12 was revealed to significantly increase the expression level of the pro-inflammatory genes CCR1, CCR3, 
TNF, IL5, IL13, ERAP1, and NUDT2, while decreasing the expression level of IL10 in eQTL analyses (Figs S8, S9, 
and Supplementary information 4).
In conclusion, intestinal BD shares common pathogenic pathways with IBD and BD without intestinal 
involvement, but in a different manner, with distinct genetic architectures. Several loci previously suggested by 
GWAS4,5 did not show a significant association with any BD subtypes in this study, which might be due to the 
multiple factors involved in disease development and the limited sample size. Thus, large multi-center replication 
studies and additional functional experiments are warranted to validate our findings.
This is the first study elucidating specific genetic polymorphisms contributing to intestinal involvement in 
BD. Our study provides the first notable evidence that there are specific genetic susceptibility loci associated 
with intestinal involvement in patients with BD, and that NAALADL2 and YIPF7 are strong candidates as causal 
variants of intestinal BD development. The GWAS results genetically separated intestinal BD and BD without 
intestinal involvement. We also identified other independent genetic variants associated with the development 
of intestinal BD, which showed a partial overlap with IBD-associated genetic variants. This study provides new 
insights into the pathogenic mechanisms of intestinal BD and IBD, which should prove useful for establishing 
new diagnostic and therapeutic strategies.
Methods
Study subjects and DNA extraction. A total of 533 BD patients of Korean descent, including 238 cases 
of BD without intestinal involvement and 295 cases of intestinal BD, were enrolled from the Behçet’s Disease 
Clinic of Yonsei University College of Medicine, Severance Hospital, Seoul, Korea between June 2006 and August 
2013. Intestinal BD was diagnosed according to established criteria based on colonoscopic features and clinical 
manifestations7. Only patients who were finally classified as “definite” or “probable” types were included in this 
study. The Institutional Review Board of Severance Hospital, Yonsei University approved this study (IRB approval 
number: 4-2013-0805). All patients and controls provided written informed consent and all methods were per-
formed in accordance with the relevant guidelines and regulations. Genomic DNA was extracted from whole 
blood samples, using the DNA blood maxi kit from Qiagen (Santa Clara, CA, USA).
GWAS. Genotyping was performed on specimens from 199 patients with BD (100 BD patients without intes-
tinal involvement and 99 patients with intestinal BD), using the Affymetrix Whole-Genome-Wide Human SNP 
Array 6.0 (Affymetrix, Santa Clara, CA, USA). All samples showed call rates of > 95% and were finally included in 
the case–control analysis. After excluding controls with < 95% call rates or mismatched sex and subjects who were 
potential relatives, a total of 597 control samples out of 600 Korean individuals were entered into the case–control 
analysis. Quality control methods for the GWAS, PCA, and imputation analysis are described in the Supporting 
Methods, Supporting information 1.
SNP selection and validation study. Forty-four SNPs, including those derived from our GWAS and 
those previously reported as significant elsewhere, were validated on the same platform, using an independ-
ent cohort of samples from 138 BD patients without intestinal involvement and 196 BD patients with intestinal 
involvement. The details of SNP selection, validation, and haplotype analysis are described in the Supporting 
Methods, Supporting Information 1.
In vitro and in vivo experiments. The HT-29 cell line (Korean Cell Line Bank, Seoul, Korea) was main-
tained at 37 °C in Dulbecco’s modified Eagle’s medium supplemented with 10% heat-inactivated fetal bovine 
serum and 1% antibiotics in a humidified atmosphere of 5% CO2.
Knockdown of a specific gene was achieved by 24-h transfection of siRNA or a non-targeting control 
(AccuTarget, Bioneer, Daejeon, Korea) into HT-29 cells. To assess inflammatory responses, the cell culture 
medium was replaced with medium containing LPS (1–2 μ g/mL) at 24 h post-transfection. Cells were harvested 
at 3 h for quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis and at 24 h for immu-
nostaining after LPS treatment.
Methods for immunohistochemical staining, qRT-PCR, and colitis mouse models are provided in the 
Supporting methods, Supporting Information 1. All experiments using animals were reviewed and approved 
by the Institutional Animal Care and Use Committee of Yonsei University Severance Hospital, Seoul, Korea 
(IACUC Approval No: 2013-0166) and all methods were performed in accordance with the relevant guidelines 
and regulations.
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In silico analyses of SNP functions, networks, and pathways. In silico analyses to explore SNP func-
tions are described in the Supporting Methods, Supporting Information 1. To establish the biological relevance 
of the selected SNPs in disease pathogenesis, the possible functional consequences of the 44 selected SNPs were 
explored. Biological pathways were analyzed using IPA (ver. 23814503, http://www.ingenuity.com/) to evaluate 
whether these sub-networks are biologically meaningful by comparing the functional relationships between con-
stituent genes identified from the GWAS. Gene lists from our study and ‘Reported Gene’ lists of BD and IBD from 
a GWAS catalog (http://www.genome.gov/gwastudies) were entered into the IPA database. Enrichment of focus 
genes and functional categories were also evaluated in the IPA Knowledge Base. The network score or P value 
represents the significance of focus gene enrichment.
Statistical analysis. Statistical significance of the association of selected SNPs with a disease or disease 
subset was determined by the chi-square test. Logistic regression analysis was used to obtain the OR, 95% 
confidence interval for the OR, and corresponding P values between cases and controls regarding the selected 
SNPs. Significant P values in association analysis for combined samples were computed by chi-square and 
Cochran-Mantel-Haenszel tests. The prognosis of intestinal BD was analyzed by the Kaplan–Meier method 
with differences determined by the log-rank test. Details are described in the Supporting Methods, Supporting 
Information 1.
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